Stockscreener 앱 받기
72.86
0.37%
0.27
전일 마감가:
$72.59
열려 있는:
$73.47
하루 거래량:
4.80M
Relative Volume:
0.92
시가총액:
$28.11B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
31.16
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
-1.19%
1개월 성능:
+22.49%
6개월 성능:
+11.25%
1년 성능:
-15.02%
1일 변동 폭
$72.52
$75.44
1주일 범위
$71.53
$76.34
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.86 | 28.01B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
91.07 | 158.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.66 | 115.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.67 | 105.19B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.55 | 72.61B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.96 | 50.35B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Is DexCom stock underperforming the Dow? - MSN
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Here's why you should retain DexCom stock in your portfolio - MSN
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
DexCom, Inc. Announces Results From CONNECT Randomized Controlled Trial Demonstrating Use Of Dexcom G7 Leads To Clinically And Statistically Significant Reduction In A1C And Improvement In Glucose Control Among People With Type 2 Diabetes N - marketscreener.com
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Yahoo Finance
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - 01net
Dexcom Reaffirms CGM Benefits for All People With Diabetes and C - GuruFocus
Dexcom to present diabetes study, launch new app, acquire Nutrisense - Investing.com
Elliott strikes Dexcom board settlement after taking stake - MSN
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative? - Yahoo Finance
Dexcom Inc. stock (US2521311074): customer advisory report and recent trading in focus - AD HOC NEWS
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
The FDA Has Issued a Warning on 2 Popular Glucose Monitors. You Won't Believe Why. - Men's Health
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience - 01net
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $85 - Moomoo
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - TMX Newsfile
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom Inc. - Moomoo
DexCom (NASDAQ: DXCM) director receives 5,605 RSUs equity grant - Stock Titan
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Here's why you should hold DexCom stock in your portfolio for now - MSN
Dexcom Inc. stock (US2521311074): shares trade mixed as investors look beyond latest earnings and gu - AD HOC NEWS
DexCom, Inc. (DXCM) Investor Outlook: A Healthcare Stock With 12.28% Upside Potential - DirectorsTalk Interviews
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Dexcom Inc. stock (US2521311074): institutional buying and technical picture on Nasdaq - AD HOC NEWS
Stolen medical devices that failed quality control were sold to the public - Yahoo
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
How Investors May Respond To DexCom (DXCM) Global App Recalls Over Delayed Glucose Alerts - Sahm
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom Inc. stock (US2521311074): shares edge lower after recent Nasdaq volatility - AD HOC NEWS
Dexcom, Inc. 8-K Filing Summary: Company Details, Stock Info, and Regulatory Compliance (May 27, 2026) - Minichart
DexCom, Inc. (DXCM) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Dexcom Shareholders Approve Board, Auditor and Compensation - TipRanks
Dexcom (NASDAQ: DXCM) investors approve board slate, auditor and executive pay - Stock Titan
Dexcom Discovers Theft of Scrapped G7 CGM Sensors - Medical Product Outsourcing
Citigroup Adjusts Price Target on DexCom to $84 From $79, Maintains Buy Rating - marketscreener.com
Signos raises $20M, expands Dexcom partnership for weight loss - qz.com
Dexcom says some CGM sensors intended for scrap stolen and resold - MSN
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) CEO has shares withheld to cover RSU taxes - Stock Titan
Dexcom (DXCM) EVP has 1,451 shares withheld for RSU tax obligations - Stock Titan
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Coleman Jon | EVP, Chief Commercial Officer |
Jun 03 '26 |
Sale |
73.00 |
4,912 |
358,576 |
100,361 |
1.35%
1.70%
자본화:
|
볼륨(24시간):